Golden Biotechnology Corporation
Golden Biotechnology Corporation engages in research and development of new drug in Taiwan. The company offers Antroquinonol for the treatment of pancreatic cancer, acute myeloid leukemia, blood diseases, non-small cell lung cancer, COVID-19, and other diseases. It is also involved in development and sale of health foods and supplements, as well as provides products for oncology, infectious, and … Read more
Golden Biotechnology Corporation (4132) - Net Assets
Latest net assets as of June 2024: NT$240.72 Million TWD
Based on the latest financial reports, Golden Biotechnology Corporation (4132) has net assets worth NT$240.72 Million TWD as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$577.95 Million) and total liabilities (NT$337.23 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$240.72 Million |
| % of Total Assets | 41.65% |
| Annual Growth Rate | -12.39% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 31.25 |
Golden Biotechnology Corporation - Net Assets Trend (2019–2023)
This chart illustrates how Golden Biotechnology Corporation's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Golden Biotechnology Corporation (2019–2023)
The table below shows the annual net assets of Golden Biotechnology Corporation from 2019 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | NT$402.10 Million | -47.41% |
| 2022-12-31 | NT$764.67 Million | -26.18% |
| 2021-12-31 | NT$1.04 Billion | +17.68% |
| 2020-12-31 | NT$880.27 Million | +29.00% |
| 2019-12-31 | NT$682.39 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Golden Biotechnology Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 49114900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | NT$1.42 Billion | 353.71% |
| Other Comprehensive Income | NT$-8.04 Million | -2.00% |
| Total Equity | NT$402.10 Million | 100.00% |
Golden Biotechnology Corporation Competitors by Market Cap
The table below lists competitors of Golden Biotechnology Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Besiktas Futbol Yatirimlari Sanayi ve Ticaret AS
IS:BJKAS
|
$54.16 Million |
|
Tofu Restaurant Co Ltd
TWO:2752
|
$54.16 Million |
|
Laboratorio Reig Jofre S.A
MC:RJF
|
$54.17 Million |
|
AB VILKUSKIU PIEN.EO 029
F:UDW
|
$54.19 Million |
|
KIRAC GALVANIZ
IS:TCKRC
|
$54.14 Million |
|
Two Rivers Financial Group Inc
PINK:TRVR
|
$54.12 Million |
|
Tien Giang Investment and Construction JSC
VN:THG
|
$54.10 Million |
|
GCT Semiconductor Holding Inc
NYSE:GCTS
|
$54.10 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Golden Biotechnology Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 764,674,000 to 402,104,000, a change of -362,570,000 (-47.4%).
- Net loss of 361,642,000 reduced equity.
- Other comprehensive income decreased equity by 864,999.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-361.64 Million | -89.94% |
| Other Comprehensive Income | NT$-865.00K | -0.22% |
| Other Changes | NT$-63.00K | -0.02% |
| Total Change | NT$- | -47.41% |
Book Value vs Market Value Analysis
This analysis compares Golden Biotechnology Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.55x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 2.16x to 4.55x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | NT$5.94 | NT$12.85 | x |
| 2020-12-31 | NT$7.00 | NT$12.85 | x |
| 2021-12-31 | NT$7.83 | NT$12.85 | x |
| 2022-12-31 | NT$5.38 | NT$12.85 | x |
| 2023-12-31 | NT$2.82 | NT$12.85 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Golden Biotechnology Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -89.94%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -570.15%
- • Asset Turnover: 0.09x
- • Equity Multiplier: 1.78x
- Recent ROE (-89.94%) is below the historical average (-50.92%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -41.78% | -342.31% | 0.09x | 1.43x | NT$-353.36 Million |
| 2020 | -44.46% | -440.61% | 0.07x | 1.35x | NT$-479.40 Million |
| 2021 | -42.85% | -542.80% | 0.05x | 1.44x | NT$-547.42 Million |
| 2022 | -35.55% | -124.81% | 0.20x | 1.44x | NT$-348.34 Million |
| 2023 | -89.94% | -570.15% | 0.09x | 1.78x | NT$-401.85 Million |
Industry Comparison
This section compares Golden Biotechnology Corporation's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $4,528,453,600
- Average return on equity (ROE) among peers: 3.91%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Golden Biotechnology Corporation (4132) | NT$240.72 Million | -41.78% | 1.40x | $54.15 Million |
| Grape King Bio Ltd (1707) | $11.79 Billion | 12.28% | 0.30x | $413.97 Million |
| Standard Chemical & Pharmaceutical Co Ltd (1720) | $8.14 Billion | 10.26% | 0.37x | $160.24 Million |
| Maywufa Co Ltd (1731) | $2.11 Billion | 8.22% | 0.51x | $41.33 Million |
| Allied Biotech Corporation (1780) | $1.17 Billion | 8.33% | 0.78x | $47.92 Million |
| ScinoPharm Taiwan Ltd (1789) | $9.38 Billion | 5.16% | 0.21x | $180.77 Million |
| GeneFerm Biotechnology Co Ltd (1796) | $396.19 Million | 1.14% | 1.48x | $24.30 Million |
| Easywell Biomedicals Inc. (1799) | $696.90 Million | -39.00% | 0.68x | $62.14 Million |
| LIWANLI Innovation Co Ltd (3054) | $799.59 Million | 4.48% | 0.55x | $49.55 Million |
| YungShin Global Holding Corp (3705) | $4.70 Billion | 6.21% | 0.18x | $292.12 Million |
| TTY Biopharm Co Ltd (4105) | $6.11 Billion | 22.00% | 0.56x | $486.74 Million |